New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 19, 2012
09:59 EDTWLP, SQNMWellpoint deems Sequenom pre-natal tests medically necessary for some patients
In a medical policy update with an effective date of Dec. 19, 2012, health insurer Wellpoint (WLP) stated that it views cell-free fetal DNA-based prenatal screening for fetal aneuploidies, including but not limited to Trisomy 13, Trisomy 18 and Trisomy 21, medically necessary for its members when certain criteria are met. Wellpoint stated there are currently several commercially available laboratory developed tests which analyze circulating cell-free DNA to identify increased representation of various chromosomes, including but not necessarily limited to the Sequenom's (SQNM) MaterniT21 Test and its MaterniT21 Plus Test, among others from Verinata Health and Aria Diagnostics. In early morning trading, shares of Sequenom rose 32c, or 6.84%, to $4.96, with the strength being attributed by some to Wellpoint's approval. Reference Link
News For SQNM;WLP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
12:39 EDTWLPHHS Secretary orders Medicare to change payment method, WSJ says
Subscribe for More Information
January 23, 2015
15:46 EDTSQNMPiper Jaffray's medtech analysts hold an analyst/industry conference call
Subscribe for More Information
January 22, 2015
07:04 EDTSQNMSequenom and Cypher Genomics sign prenatal test development agreement
Subscribe for More Information
January 20, 2015
13:45 EDTSQNMIllumina rises as genomics project seen being announced in State of the Union
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use